1. Home
  2. People
  3. Toulouse, Vianney

Vianney Toulouse

Partner

Paris

Vianney Toulouse is a Paris-based partner specializing in mergers and acquisitions, private equity and life sciences transactions.

Vianney focuses his practice on corporate transactions, including mergers and acquisitions, private equity, and capital markets with a specific focus on life sciences transactions. He also advises French and international, listed and unlisted companies and investment funds on corporate law and governance matters.

Vianney regularly assists French and multinational corporations, as well as private equity funds, with their investments across a range of industries and in particular in the life sciences industry. He also advises French biotech, medtech and healthtech companies in their financing transactions.

In The Legal 500 2023, clients highlighted that “Vianney is an excellent professional, who goes into his files in depth. He is a fine negotiator with very good interpersonal skills.”

    • ARCHIMED on acquisition of a majority stake in Stago Group.*
    • Affluent Medical on Caranx Medical and Artedrone acquisitions and a simultaneous fundraising.*
    • Mauna Kea Technologies on its refinancing.*
    • Abivax on its US$747.5 million public offering on Nasdaq.*
    • ARCHIMED on investment in Laboratoires Rivadis group.*
    • Abivax on the largest-ever Euronext Paris single listing biotech private placement.*
    • Cathay Capital, a global investment firm, in connection with the sale of the Cenexi group to the Indian group Gland Pharma, controlled by the Chinese conglomerate Fosun.*
    • ARCHIMED, a leading investment firm exclusively dedicated to the healthcare sector, in connection with the purchase of a majority stake in CARSO, a French leader in analytical services, through its €1 billion MED Platform I fund.*
    • Abivax in connection with its oversubscribed capital increase of €60 million and convertible bonds of €25 million, totalling €85 million in new financing;*
    • Interchim, a leading family office producing life sciences equipment, along with its shareholders, in connection with its sale to the Chinese group Junzheng listed on the Shanghai Stock Exchange, in partnership with Advion.*
    • Robocath in connection with its €40 million (US$43 million) series C round of financing, as well as in its strategic agreement signed with MicroPort to set up a China-based joint-venture company.*
    • NHCO Nutrition's shareholders on the sale of 100% of its share capital to the group Chiesi.*
    • Neovia on an exclusive negotiation agreement with Archer Daniels Midland company.*
    • Vexim, a French medtech company, in connection with the €183 million tender offer from Stryker Corporation.*

    *experience prior to joining Orrick

News